Caidya Strengthens Therapeutic Leadership: Names Adam Callahan Head of Oncology and Hematology
RALEIGH, N.C.; Mar. 13, 2025 – Caidya, a leading global, mid-sized CRO, today announced the appointment of Adam Callahan Vice President, Global Therapeutic Area Head, Oncology & Hematology. In this role, he will establish and drive strategic direction and execution for our partnerships with clients developing oncology, hematology, and cell and gene therapy treatments. Following Caidya’s recent investment of $165M from Rubicon Founders, this hiring helps Caidya’s continue, and improve its ability to deliver exceptional outcomes for sponsors and patients.
Adam brings his expertise and nearly 25 years of experience in clinical development program and portfolio management, and clinical operations in the biopharma and CRO industries to Caidya as he leads these important therapeutic areas. He has a strong record of building high-performing, global teams that drive clinical programs for commercialization of therapies along with adeptness in molecule-to-market strategies, operational excellence, and regulatory compliance.
Caidya’s Chief Operations Officer, Gaurav Sharma , said, “I’m excited to have Adam join our team as he will, no doubt, continue and expand our ability to deliver an exceptional experience for our clients conducting oncology, hematology and cell and gene studies.”
“It’s great to be joining Caidya where I can continue with my unwavering commitment to positively impact the lives of patients,” said Callahan. “I’ll be working with our talented operational, medical and scientific teams to collaborate with biopharma partners and bring innovative treatments to patients.”
About Caidya
Caidya is a global, mid-sized clinical research organization (CRO) dedicated to advancing healthcare innovation and partnering with biopharma sponsors to bring innovative therapies for unmet medical conditions to our global community. With full-service capabilities and a strategic footprint – with 23 locations and conducting studies in more than 40 countries and regions – our global network provides broad access to diverse patient populations across the Americas, Europe, and APAC. Caidya’s in-depth therapeutic and operational expertise spans oncology and hematology, cell and gene therapy, rare and pediatric diseases as well as other fast-growing therapeutic areas where we help our biopharma partners conduct studies with greater efficiency and confidence.
Caidya delivers comprehensive clinical trial services from regulatory strategy and submissions, medical affairs, clinical operations, data management, biometrics, pharmacovigilance, and quality management, through post-approval surveillance. Our data-driven, evidence-based decision making ensures the highest quality standards across all stages of the drug development process.
MEDIA CONTACT:
Roger Boutin
VP, Corporate Marketing, Caidya